AU4578197A - Pharmaceutical compositions comprising hmg-coa reductase inhibitors, in particular fluvastatin - Google Patents
Pharmaceutical compositions comprising hmg-coa reductase inhibitors, in particular fluvastatinInfo
- Publication number
- AU4578197A AU4578197A AU45781/97A AU4578197A AU4578197A AU 4578197 A AU4578197 A AU 4578197A AU 45781/97 A AU45781/97 A AU 45781/97A AU 4578197 A AU4578197 A AU 4578197A AU 4578197 A AU4578197 A AU 4578197A
- Authority
- AU
- Australia
- Prior art keywords
- hmg
- pharmaceutical compositions
- coa reductase
- reductase inhibitors
- fluvastatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 title 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
- 229960003765 fluvastatin Drugs 0.000 title 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9603668 | 1996-10-08 | ||
| SE9603668A SE9603668D0 (en) | 1996-10-08 | 1996-10-08 | Pharmaceutical compositions |
| PCT/SE1997/001605 WO1998015290A1 (en) | 1996-10-08 | 1997-09-24 | PHARMACEUTICAL COMPOSITIONS COMPRISING HMG-CoA REDUCTASE INHIBITORS, IN PARTICULAR FLUVASTATIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU4578197A true AU4578197A (en) | 1998-05-05 |
Family
ID=20404166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU45781/97A Abandoned AU4578197A (en) | 1996-10-08 | 1997-09-24 | Pharmaceutical compositions comprising hmg-coa reductase inhibitors, in particular fluvastatin |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU4578197A (en) |
| SE (1) | SE9603668D0 (en) |
| WO (1) | WO1998015290A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
| EP1940391A4 (en) * | 2005-08-05 | 2010-01-20 | Orbus Pharma Inc | Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor |
| WO2009000286A1 (en) * | 2007-06-25 | 2008-12-31 | Parmatheen S.A. | Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0465096A1 (en) * | 1990-06-26 | 1992-01-08 | Merck & Co. Inc. | Plasma cholesterol level lowering composition |
| HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
-
1996
- 1996-10-08 SE SE9603668A patent/SE9603668D0/en unknown
-
1997
- 1997-09-24 AU AU45781/97A patent/AU4578197A/en not_active Abandoned
- 1997-09-24 WO PCT/SE1997/001605 patent/WO1998015290A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| SE9603668D0 (en) | 1996-10-08 |
| WO1998015290A1 (en) | 1998-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU8054298A (en) | Primal tracking | |
| HUP0000167A3 (en) | Pyrroles as spla2 inhibitors, and pharmaceutical compositions containing them | |
| AU4791797A (en) | 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors | |
| AU4215800A (en) | Dynamic server organization | |
| HUP0104258A3 (en) | Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor | |
| AU4762797A (en) | Pharmaceutical compositions | |
| AU1940701A (en) | Methods and systems for market clearance | |
| AU2967597A (en) | Pharmaceutical compositions | |
| AU5991699A (en) | Quinolizinones as integrin inhibitors | |
| AU5326100A (en) | Pharmaceutical compositions and methods for use | |
| AU2421797A (en) | Spirocycle integrin inhibitors | |
| AU2058992A (en) | HMG-COA reductase inhibitors | |
| AU5565099A (en) | Pharmaceutical compositions and methods for use | |
| GB9827391D0 (en) | Aldose reductase inhibitors and pharmaceutical compositions | |
| AU8107998A (en) | Pharmaceutical compositions | |
| AU3777897A (en) | Pharmaceutical compositions | |
| AU4326197A (en) | Pharmaceutical compositions | |
| AU7761398A (en) | Hmg-coa reductase inhibitor preparation process | |
| AU5317598A (en) | Novel pharmaceutical compositions | |
| AU5213300A (en) | 2-nh-pyridones and pyrimidones as mrs inhibitors | |
| AU1824201A (en) | Polymorphisms in the human HMG-COA reductase gene | |
| AU3235100A (en) | Prothease inhibitors | |
| AU1013997A (en) | Amylase inhibitors | |
| AU4578197A (en) | Pharmaceutical compositions comprising hmg-coa reductase inhibitors, in particular fluvastatin | |
| AU4543500A (en) | Pharmaceutical compositions and uses |